{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:37:13Z","timestamp":1793824633812,"version":"4.6.1"},"reference-count":150,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012152","name":"National Postdoctoral Program for Innovative Talents","doi-asserted-by":"publisher","award":["GZB20230642"],"award-info":[{"award-number":["GZB20230642"]}],"id":[{"id":"10.13039\/501100012152","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82503827"],"award-info":[{"award-number":["82503827"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403929"],"award-info":[{"award-number":["82403929"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["8250101942"],"award-info":[{"award-number":["8250101942"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2025T180593"],"award-info":[{"award-number":["2025T180593"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2024M763330"],"award-info":[{"award-number":["2024M763330"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Zhejiang Province Natural Science Foundation","doi-asserted-by":"publisher","award":["LQ24H160007"],"award-info":[{"award-number":["LQ24H160007"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.isci.2025.114203","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T07:53:05Z","timestamp":1764057185000},"page":"114203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Advances in the clinical application of bispecific antibodies in cancer therapy"],"prefix":"10.1016","volume":"28","author":[{"given":"Shiqi","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengke","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kongming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6999-3020","authenticated-orcid":false,"given":"Tianye","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2025.114203_bib1","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.isci.2025.114203_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12081801","article-title":"Overcoming Cancer Resistance: Strategies and Modalities for Effective Treatment","volume":"12","author":"Koirala","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.isci.2025.114203_bib3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13045-015-0141-5","article-title":"Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future","volume":"8","author":"Goel","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.isci.2025.114203_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12092158","article-title":"Revolutionizing Cancer Treatment: Recent Advances in Immunotherapy","volume":"12","author":"Ghemrawi","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.isci.2025.114203_bib5","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S0140-6736(16)31473-8","article-title":"New and emerging targeted treatments in advanced non-small-cell lung cancer","volume":"388","author":"Hirsch","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2025.114203_bib6","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13045-017-0444-9","article-title":"Chimeric antigen receptor T cells: a novel therapy for solid tumors","volume":"10","author":"Yu","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.isci.2025.114203_bib7","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1021\/acs.jmedchem.4c02425","article-title":"Antibody-Vincristine Conjugates as Potent Anticancer Therapeutic Agents","volume":"68","author":"Boos","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.isci.2025.114203_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009901","article-title":"Engineered oncolytic virus expressing B7H3-targeting BiTE enhances antitumor T-cell immune response","volume":"12","author":"Zhu","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.isci.2025.114203_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/btpr.3515","article-title":"General strategies for IgG-like bispecific antibody purification","volume":"41","author":"Li","year":"2025","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.isci.2025.114203_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005543","article-title":"Anti-TGF-\u03b2\/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer","volume":"10","author":"Yi","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.isci.2025.114203_bib11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2019.04.006","article-title":"A review of bispecific antibodies and antibody constructs in oncology and clinical challenges","volume":"201","author":"Suurs","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.isci.2025.114203_bib12","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1158\/1535-7163.MCT-12-0692","article-title":"Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production","volume":"11","author":"Gleason","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.isci.2025.114203_bib13","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.isci.2025.114203_bib14","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","article-title":"T-cell-engaging bispecific antibodies in cancer","volume":"402","author":"van de Donk","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2025.114203_bib15","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.drudis.2015.02.008","article-title":"Bispecific antibodies","volume":"20","author":"Kontermann","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.isci.2025.114203_bib16","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13045-017-0522-z","article-title":"Recent advances of bispecific antibodies in solid tumors","volume":"10","author":"Yu","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.isci.2025.114203_bib17","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrd.2017.227","article-title":"Next generation antibody drugs: pursuit of the 'high-hanging fruit","volume":"17","author":"Carter","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.isci.2025.114203_bib18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.copbio.2019.11.020","article-title":"Bispecific antibodies in cancer immunotherapy","volume":"65","author":"Rader","year":"2020","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.isci.2025.114203_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13020287","article-title":"Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors","volume":"13","author":"Middelburg","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.isci.2025.114203_bib20","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13045-022-01363-8","article-title":"Combination of oral STING agonist MSA-2 and anti-TGF-\u03b2\/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors","volume":"15","author":"Yi","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.isci.2025.114203_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202408598","article-title":"Blockade of CCR5(+) T Cell Accumulation in the Tumor Microenvironment Optimizes Anti-TGF-\u03b2\/PD-L1 Bispecific Antibody","volume":"11","author":"Yi","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.isci.2025.114203_bib22","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2025.114203_bib23","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1158\/2159-8290.CD-20-1808","article-title":"Therapeutic Targeting of the Tumor Microenvironment","volume":"11","author":"Bejarano","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.isci.2025.114203_bib24","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nrc3236","article-title":"Antibody therapy of cancer","volume":"12","author":"Scott","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.isci.2025.114203_bib25","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.tibtech.2003.08.007","article-title":"Domain antibodies: proteins for therapy","volume":"21","author":"Holt","year":"2003","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.isci.2025.114203_bib26","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","article-title":"The making of bispecific antibodies","volume":"9","author":"Brinkmann","year":"2017","journal-title":"mAbs"},{"key":"10.1016\/j.isci.2025.114203_bib27","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/B978-0-12-386483-3.00004-5","article-title":"Aggregation, stability, and formulation of human antibody therapeutics","volume":"84","author":"Lowe","year":"2011","journal-title":"Adv. Protein Chem. Struct. Biol."},{"key":"10.1016\/j.isci.2025.114203_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/biom10030360","article-title":"Bispecific Antibodies and Antibody-Drug Conjugates for Cancer Therapy: Technological Considerations","volume":"10","author":"Shim","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.isci.2025.114203_bib29","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40364-021-00294-9","article-title":"The landscape of bispecific T cell engager in cancer treatment","volume":"9","author":"Zhou","year":"2021","journal-title":"Biomark. Res."},{"key":"10.1016\/j.isci.2025.114203_bib30","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1182\/blood.2022019082","article-title":"Reinforced antimyeloma therapy via dual-lymphoid activation mediated by a panel of antibodies armed with bridging-BiTE","volume":"142","author":"Konishi","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.isci.2025.114203_bib31","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jmb.2010.04.001","article-title":"Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion","volume":"399","author":"Johnson","year":"2010","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.isci.2025.114203_bib32","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1172\/JCI82314","article-title":"Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells","volume":"125","author":"Sung","year":"2015","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.isci.2025.114203_bib33","doi-asserted-by":"crossref","first-page":"728","DOI":"10.4161\/mabs.28591","article-title":"A novel tetravalent bispecific TandAb (CD30\/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells","volume":"6","author":"Reusch","year":"2014","journal-title":"mAbs"},{"key":"10.1016\/j.isci.2025.114203_bib34","doi-asserted-by":"crossref","first-page":"5829","DOI":"10.1158\/1078-0432.CCR-16-0350","article-title":"Characterization of CD33\/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia","volume":"22","author":"Reusch","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2025.114203_bib35","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13045-017-0397-z","article-title":"Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3\/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor D-1-methyl-tryptophan","volume":"10","author":"Zhang","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.isci.2025.114203_bib36","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.114203_bib37","first-page":"1","article-title":"Boosting therapeutic potency of antibodies by taming Fc domain functions","volume":"51","author":"Kang","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.isci.2025.114203_bib38","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s13238-017-0473-8","article-title":"IgG Fc engineering to modulate antibody effector functions","volume":"9","author":"Wang","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.isci.2025.114203_bib39","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jmb.2012.04.020","article-title":"Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair","volume":"420","author":"Strop","year":"2012","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.isci.2025.114203_bib40","doi-asserted-by":"crossref","first-page":"182","DOI":"10.4161\/mabs.4.2.19000","article-title":"Dual targeting strategies with bispecific antibodies","volume":"4","author":"Kontermann","year":"2012","journal-title":"mAbs"},{"key":"10.1016\/j.isci.2025.114203_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057479","article-title":"Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity","volume":"8","author":"Sampei","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2025.114203_bib42","doi-asserted-by":"crossref","first-page":"11187","DOI":"10.1073\/pnas.1019002108","article-title":"Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies","volume":"108","author":"Schaefer","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2025.114203_bib43","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/nbt1345","article-title":"Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin","volume":"25","author":"Wu","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.isci.2025.114203_bib44","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.4161\/mabs.36089","article-title":"An affibody-adalimumab hybrid blocks combined IL-6 and TNF-triggered serum amyloid A secretion in vivo","volume":"6","author":"Yu","year":"2014","journal-title":"mAbs"},{"key":"10.1016\/j.isci.2025.114203_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1005800","article-title":"Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors","volume":"13","author":"Hambach","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2025.114203_bib46","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nri2761","article-title":"Therapeutic antibodies for autoimmunity and inflammation","volume":"10","author":"Chan","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.isci.2025.114203_bib47","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.isci.2025.114203_bib48","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2025.114203_bib49","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0140-6736(24)02135-4","article-title":"Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China","volume":"404","author":"Wu","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2025.114203_bib50","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1038\/s41591-024-03007-5","article-title":"Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b\/2 COMPASSION-04 trial","volume":"30","author":"Gao","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2025.114203_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1238667","article-title":"The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib\/II single-arm clinical trial","volume":"14","author":"Qiao","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2025.114203_bib52","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1158\/2159-8290.CD-20-1680","article-title":"The Next Decade of Immune Checkpoint Therapy","volume":"11","author":"Sharma","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.isci.2025.114203_bib53","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1158\/1078-0432.CCR-16-1272","article-title":"Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody","volume":"23","author":"Segal","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2025.114203_bib54","series-title":"A Phase 1\/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination with Cemiplimab (Anti\u2013PD-1) in Patients with Advanced Solid Tumors: Trial-In-Progress Update","author":"Segal","year":"2023"},{"key":"10.1016\/j.isci.2025.114203_bib55","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","article-title":"A phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Rothe","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.isci.2025.114203_bib56","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1158\/1078-0432.CCR-24-1991","article-title":"First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors","volume":"31","author":"El-Khoueiry","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2025.114203_bib57","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202501819","article-title":"Bispecific Antibody Targeting VEGF\/TGF-\u03b2 Synergizes with Local Radiotherapy: Turning Tumors from Cold to Inflamed and Amplifying Abscopal Effects","volume":"12","author":"Lyu","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.isci.2025.114203_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.719116","article-title":"Co-Stimulatory Bispecific Antibodies Induce Enhanced T Cell Activation and Tumor Cell Killing in Breast Cancer Models","volume":"12","author":"Warwas","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2025.114203_bib59","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1158\/2159-8290.CD-20-0116","article-title":"Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC","volume":"10","author":"Yun","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.isci.2025.114203_bib60","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1200\/JCO.2022.40.16_suppl.105","article-title":"Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers","volume":"40","author":"Schram","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2025.114203_bib61","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adh1988","article-title":"Immunocytokines with target cell-restricted IL-15 activity for treatment of B cell malignancies","volume":"16","author":"Zekri","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.isci.2025.114203_bib62","article-title":"A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2R\u03b1 strengthens T cell-mediated anti-tumor therapies","volume":"5","author":"Wu","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.isci.2025.114203_bib63","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/s41416-025-03125-y","article-title":"T cell engagers: expanding horizons in oncology and beyond","volume":"133","author":"Albayrak","year":"2025","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.isci.2025.114203_bib64","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody-Drug Conjugates (ADCs): current and future biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.isci.2025.114203_bib65","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003771","article-title":"Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies","volume":"10","author":"Park","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.isci.2025.114203_bib66","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003468","article-title":"Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer","volume":"9","author":"Liu","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.isci.2025.114203_bib67","article-title":"Reprogramming the Tumor Immune Microenvironment with ICAM-1-Targeted Antibody\u2012Drug Conjugates and B7-H3-CD3 Bispecific Antibodies","volume":"12","author":"Zhou","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.isci.2025.114203_bib68","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/13543784.2025.2511179","article-title":"Emerging GPRC5D-Targeted therapies for multiple myeloma: a comprehensive review","volume":"34","author":"Pan","year":"2025","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.isci.2025.114203_bib69","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/s42003-024-06682-9","article-title":"CD3-engaging bispecific antibodies trigger a paracrine regulated wave of T-cell recruitment for effective tumor killing","volume":"7","author":"Liao","year":"2024","journal-title":"Commun. Biol."},{"key":"10.1016\/j.isci.2025.114203_bib70","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.trecan.2024.07.002","article-title":"Bispecific antibodies: advancing precision oncology","volume":"10","author":"Herrera","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.isci.2025.114203_bib71","article-title":"Natural killer cell engagers for cancer immunotherapy","volume":"14","author":"Nikkhoi","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.isci.2025.114203_bib72","doi-asserted-by":"crossref","first-page":"181","DOI":"10.20892\/j.issn.2095-3941.2023.0002","article-title":"Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy","volume":"20","author":"Zhang","year":"2023","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.isci.2025.114203_bib73","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.pharmthera.2012.07.013","article-title":"Blinatumomab: a historical perspective","volume":"136","author":"Nagorsen","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.isci.2025.114203_bib74","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen \u00d7 CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2025.114203_bib75","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1158\/2326-6066.CIR-24-0298","article-title":"NI-3201 Is a Bispecific Antibody Mediating PD-L1-Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control","volume":"13","author":"Majocchi","year":"2025","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.isci.2025.114203_bib76","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa4802","article-title":"Anti-CD20\/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies","volume":"7","author":"Sun","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.isci.2025.114203_bib77","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1182\/bloodadvances.2020002393","article-title":"Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma","volume":"4","author":"Pillarisetti","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.isci.2025.114203_bib78","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008037","article-title":"Phase 1a dose escalation study of ivonescimab (AK112\/SMT112), an anti-PD-1\/VEGF-A bispecific antibody, in patients with advanced solid tumors","volume":"12","author":"Frentzas","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.isci.2025.114203_bib79","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.7796.1","article-title":"Concerning immune synapses: a spatiotemporal timeline","volume":"5","author":"Ortega-Carrion","year":"2016","journal-title":"F1000Res."},{"key":"10.1016\/j.isci.2025.114203_bib80","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/cts.12877","article-title":"Quantitative Clinical Pharmacology of T-Cell Engaging Bispecifics: Current Perspectives and Opportunities","volume":"14","author":"Morcos","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.isci.2025.114203_bib81","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/s41423-024-01176-4","article-title":"Bridging the gap with multispecific immune cell engagers in cancer and infectious diseases","volume":"21","author":"Rolin","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.isci.2025.114203_bib82","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1113303","article-title":"Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager","volume":"14","author":"Xiao","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2025.114203_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111698","article-title":"An innovative antibody fusion protein targeting PD-L1, VEGF and TGF-\u03b2 with enhanced antitumor efficacies","volume":"130","author":"Fan","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.isci.2025.114203_bib84","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/0008-5472.CAN-09-0547","article-title":"Bispecific T-cell engaging antibodies for cancer therapy","volume":"69","author":"Baeuerle","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2025.114203_bib85","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13045-021-01045-x","article-title":"The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-\u03b2 and PD-L1","volume":"14","author":"Yi","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.isci.2025.114203_bib86","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12964-024-01562-5","article-title":"The enhanced antitumor activity of bispecific antibody targeting PD-1\/PD-L1 signaling","volume":"22","author":"Li","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.isci.2025.114203_bib87","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"32","author":"Topp","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2025.114203_bib88","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","article-title":"Phase I\/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed\/Refractory Acute Lymphoblastic Leukemia","volume":"34","author":"von Stackelberg","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2025.114203_bib89","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.114203_bib90","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"Gokbuget","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.isci.2025.114203_bib91","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults","volume":"383","author":"Foa","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.114203_bib92","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jama.2021.0669","article-title":"Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial","volume":"325","author":"Brown","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.isci.2025.114203_bib93","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults","volume":"391","author":"Litzow","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.114203_bib94","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","article-title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet. Haematol."},{"key":"10.1016\/j.isci.2025.114203_bib95","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.isci.2025.114203_bib96","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2020.12.022","article-title":"Long-term follow-up of blinatumomab in patients with relapsed\/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study","volume":"146","author":"Martinelli","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.isci.2025.114203_bib97","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study","volume":"40","author":"Budde","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2025.114203_bib98","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.isci.2025.114203_bib99","doi-asserted-by":"crossref","first-page":"6055","DOI":"10.1182\/bloodadvances.2023010840","article-title":"Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study","volume":"7","author":"Olszewski","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.isci.2025.114203_bib100","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41591-023-02726-5","article-title":"Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b\/2 trial","volume":"30","author":"Budde","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2025.114203_bib101","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.114203_bib102","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s40265-022-01793-1","article-title":"Teclistamab: First Approval","volume":"82","author":"Kang","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.isci.2025.114203_bib103","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1158\/1078-0432.CCR-18-0455","article-title":"CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies","volume":"24","author":"Bacac","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2025.114203_bib104","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.114203_bib105","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(24)01774-4","article-title":"Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial","volume":"404","author":"Abramson","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2025.114203_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2019.102625","article-title":"DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing","volume":"52","author":"Engelberts","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.isci.2025.114203_bib107","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2025.114203_bib108","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I\/II Trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2025.114203_bib109","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study","volume":"11","author":"Linton","year":"2024","journal-title":"Lancet. Haematol."},{"key":"10.1016\/j.isci.2025.114203_bib110","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/j.1365-2362.2012.02679.x","article-title":"Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma","volume":"42","author":"Atamaniuk","year":"2012","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.isci.2025.114203_bib111","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.114203_bib112","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/14737140.2023.2236303","article-title":"Elranatamab: a new promising BispAb in multiple myeloma treatment","volume":"23","author":"Grosicki","year":"2023","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.isci.2025.114203_bib113","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","article-title":"Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2025.114203_bib114","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2025.114203_bib115","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s40265-023-01954-w","article-title":"Elranatamab: First Approval","volume":"83","author":"Dhillon","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.isci.2025.114203_bib116","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1158\/1078-0432.CCR-22-3713","article-title":"FDA Approval Summary: Amivantamab for the Treatment of Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations","volume":"29","author":"Chon","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2025.114203_bib117","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study","volume":"39","author":"Park","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2025.114203_bib118","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1038\/s41591-023-02554-7","article-title":"Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial","volume":"29","author":"Cho","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2025.114203_bib119","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","article-title":"Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions","volume":"389","author":"Zhou","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.114203_bib120","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.isci.2025.114203_bib121","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1200\/JCO.24.01001","article-title":"Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study","volume":"42","author":"Leighl","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2025.114203_bib122","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.114203_bib123","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-20-1247","article-title":"Tebentafusp, A TCR\/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma","volume":"26","author":"Middleton","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2025.114203_bib124","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","article-title":"Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma","volume":"389","author":"Hassel","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.114203_bib125","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1038\/s41591-022-02015-7","article-title":"Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial","volume":"28","author":"Carvajal","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2025.114203_bib126","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006747","article-title":"Tebentafusp in combination with durvalumab and\/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study","volume":"11","author":"Hamid","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.isci.2025.114203_bib127","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s40265-022-01704-4","article-title":"Tebentafusp: First Approval","volume":"82","author":"Dhillon","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.isci.2025.114203_bib128","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jtho.2023.10.014","article-title":"A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC","volume":"19","author":"Wang","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.isci.2025.114203_bib129","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/jama.2024.10613","article-title":"Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial","volume":"332","author":"HARMONi-A Study Investigators","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.isci.2025.114203_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107355","article-title":"A multicenter, open-label phase Ib\/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study)","volume":"184","author":"Zhao","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.isci.2025.114203_bib131","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S1470-2045(23)00411-4","article-title":"Safety and antitumour activity of cadonilimab, an anti-PD-1\/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b\/2 trial","volume":"24","author":"Gao","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.isci.2025.114203_bib132","article-title":"A phase 1a\/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumors","volume":"4","author":"Frentzas","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.isci.2025.114203_bib133","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41416-023-02519-0","article-title":"A phase Ib\/II study of cadonilimab (PD-1\/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer","volume":"130","author":"Chen","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.isci.2025.114203_bib134","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1158\/1078-0432.CCR-23-3162","article-title":"Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study","volume":"30","author":"Lou","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2025.114203_bib135","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1200\/JCO.22.02823","article-title":"Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study","volume":"41","author":"Paz-Ares","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2025.114203_bib136","first-page":"1864","volume":"11","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.isci.2025.114203_bib137","doi-asserted-by":"crossref","first-page":"S756","DOI":"10.1016\/j.annonc.2023.09.2349","article-title":"1315MO Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)","volume":"34","author":"Schram","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.isci.2025.114203_bib138","doi-asserted-by":"crossref","first-page":"S895","DOI":"10.1016\/j.annonc.2023.09.2567","article-title":"1618P Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC)","volume":"34","author":"Schram","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.isci.2025.114203_bib139","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1475-2867-6-26","article-title":"Expression of EpCAM in uveal melanoma","volume":"6","author":"Odashiro","year":"2006","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.isci.2025.114203_bib140","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1093\/annonc\/mds178","article-title":"Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II\/III study comparing paracentesis plus catumaxomab with paracentesis alone","volume":"23","author":"Wimberger","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.isci.2025.114203_bib141","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/CJI.0000000000000236","article-title":"Cytokine Release Syndrome During Sequential Treatment With Immune Checkpoint Inhibitors and Kinase Inhibitors for Metastatic Melanoma","volume":"42","author":"Dimitriou","year":"2019","journal-title":"J. Immunother."},{"key":"10.1016\/j.isci.2025.114203_bib142","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","article-title":"Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia","volume":"45","author":"Fitzgerald","year":"2017","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.isci.2025.114203_bib143","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/17474086.2019.1585238","article-title":"Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy","volume":"12","author":"Acharya","year":"2019","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.isci.2025.114203_bib144","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1189\/jlb.1105674","article-title":"Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer","volume":"80","author":"Rose-John","year":"2006","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.isci.2025.114203_bib145","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.114203_bib146","doi-asserted-by":"crossref","DOI":"10.1016\/j.copbio.2022.102809","article-title":"Engineering antibodies for conditional activity in the solid tumor microenvironment","volume":"78","author":"Liu","year":"2022","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.isci.2025.114203_bib147","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1548446","article-title":"Improving CD3 bispecific antibody therapy in solid tumors using combination strategies","volume":"15","author":"Lloyd","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.isci.2025.114203_bib148","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13045-025-01678-2","article-title":"Anti-TGF-\u03b2\/PD-L1 bispecific antibody synergizes with radiotherapy to enhance antitumor immunity and mitigate radiation-induced pulmonary fibrosis","volume":"18","author":"Wu","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.isci.2025.114203_bib149","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s40259-025-00735-z","article-title":"Bispecific Antibodies in Hematologic Malignancies: Attacking the Frontline","volume":"39","author":"Shastri","year":"2025","journal-title":"BioDrugs"},{"key":"10.1016\/j.isci.2025.114203_bib150","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17071153","article-title":"Measurable Residual Disease Testing During Treatment with Bispecific Antibodies for Lymphoma","volume":"17","author":"Jean-Louis","year":"2025","journal-title":"Cancers (Basel)"}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004225024642?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004225024642?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T02:07:55Z","timestamp":1783476475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004225024642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":150,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2589004225024642"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2025.114203","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in the clinical application of bispecific antibodies in cancer therapy","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2025.114203","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"114203"}}